JP2008534621A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534621A5
JP2008534621A5 JP2008504498A JP2008504498A JP2008534621A5 JP 2008534621 A5 JP2008534621 A5 JP 2008534621A5 JP 2008504498 A JP2008504498 A JP 2008504498A JP 2008504498 A JP2008504498 A JP 2008504498A JP 2008534621 A5 JP2008534621 A5 JP 2008534621A5
Authority
JP
Japan
Prior art keywords
liothyronine
pharmaceutical composition
concentration
administration
exceed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534621A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/012272 external-priority patent/WO2006105482A2/en
Publication of JP2008534621A publication Critical patent/JP2008534621A/ja
Publication of JP2008534621A5 publication Critical patent/JP2008534621A5/ja
Pending legal-status Critical Current

Links

JP2008504498A 2005-03-31 2006-03-31 リオチロニンからなる放出制御型医薬組成物、並びにその製造方法及び使用方法 Pending JP2008534621A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66662105P 2005-03-31 2005-03-31
PCT/US2006/012272 WO2006105482A2 (en) 2005-03-31 2006-03-31 Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2008534621A JP2008534621A (ja) 2008-08-28
JP2008534621A5 true JP2008534621A5 (https=) 2009-05-14

Family

ID=37054215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504498A Pending JP2008534621A (ja) 2005-03-31 2006-03-31 リオチロニンからなる放出制御型医薬組成物、並びにその製造方法及び使用方法

Country Status (11)

Country Link
US (1) US20060246133A1 (https=)
EP (1) EP1863446A2 (https=)
JP (1) JP2008534621A (https=)
KR (1) KR20070119714A (https=)
CN (1) CN101175477A (https=)
AU (1) AU2006230557A1 (https=)
BR (1) BRPI0609779A2 (https=)
CA (1) CA2603313A1 (https=)
IL (1) IL185723A0 (https=)
MX (1) MX2007011826A (https=)
WO (1) WO2006105482A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
EP1958620B1 (en) * 2007-02-16 2012-04-18 CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Développement Verification method
ITMI20112066A1 (it) * 2011-11-14 2013-05-15 Altergon Sa Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4
MX2018013410A (es) * 2016-05-03 2019-06-06 Spectrix Therapeutics Llc Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.
US10695309B2 (en) * 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
US11964048B2 (en) * 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine
JP2025513255A (ja) * 2022-04-22 2025-04-24 プロレヴィ バイオ エービー 活性成分の改変放出のための組成物
CN115645361B (zh) * 2022-09-30 2023-11-21 天津市眼科医院 一种用于加强角膜生物力学性质的眼用制剂及t3的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
ATE164063T1 (de) * 1991-12-30 1998-04-15 Akzo Nobel Nv Thyroaktive zusammensetzung mit kontrollierter freigabe
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods

Similar Documents

Publication Publication Date Title
JP2015057436A5 (https=)
FI3661514T3 (fi) Mavakamteeni käytettäväksi hypertrofisen kardiomyopatian hoidossa
NO20083562L (no) Cannabinoidreseptormodulatorer
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
JP2017036288A5 (https=)
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
JP2015526458A5 (https=)
JP2021504423A5 (https=)
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
JP2024540183A5 (https=)
WO2007149283A3 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
CN110801452A (zh) 一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
JP2010518061A5 (https=)
JP2008534621A5 (https=)
JP2012527438A5 (https=)
MX2009013937A (es) Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
JP2010532348A5 (https=)
Goldschmidt et al. Compound cardiac toxicity of oral erythromycin and verapamil
Patankar et al. Delayed takotsubo cardiomyopathy caused by excessive exogenous epinephrine administration after the treatment of angioedema
JP5396387B2 (ja) 心臓不整脈を治療するためのｄ−リボースの用途
JP2023506450A5 (https=)
JP2012511571A5 (https=)
UA108980C2 (en) APPLICATION OF DONEDARONE FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS
Anderson et al. Transient ST-segment elevation resembling acute myocardial infarction in a patient with a right secondary spontaneous pneumothorax
CA2706357A1 (en) 3-(2,2,2-trimethylhydrazinium) propionate salts for treating ischemic heart disease